10-Q: LifeStance Health Posts Q3 Profit, Revenue Jumps 16%

LifeStance Health Group, Inc. reported a return to net income in the third quarter of 2025 with a 16% revenue increase, despite ongoing material weaknesses in internal financial controls.

Summary

• Total revenue increased by $51.1 million, or 16%, to $363.8 million for the three months ended September 30, 2025, compared to $312.7 million for the same period in 2024.
• For the nine months ended September 30, 2025, total revenue increased by $116.6 million, or 13%, to $1,042.1 million, up from $925.5 million in the prior year.
• The company achieved a net income of $1.077 million for the three months ended September 30, 2025, a significant improvement from a net loss of $5.957 million in the comparable 2024 period.
• The net loss for the nine months ended September 30, 2025, was reduced to $2.005 million, substantially better than the $50.331 million net loss for the nine months ended September 30, 2024.
• Adjusted EBITDA grew by 31% to $40.209 million for the three months ended September 30, 2025, from $30.713 million in the prior year, and by 25% to $108.860 million for the nine months ended September 30, 2025, from $86.969 million.
• Patient visits increased by 0.3 million (17%) to 2.3 million for the three months ended September 30, 2025, and by 0.7 million (13%) to 6.6 million for the nine months ended September 30, 2025.
• The total number of licensed mental health clinicians employed increased by a net of 764, reaching 7,996 as of September 30, 2025.
• Cash and cash equivalents increased to $203.9 million as of September 30, 2025, from $154.6 million at December 31, 2024.
• Material weaknesses in internal control over financial reporting continue to exist as of September 30, 2025, leading to a conclusion that disclosure controls and procedures were not effective.

Sentiment

Score: 6

Explanation: The company demonstrated strong operational growth and a significant turnaround in profitability, moving from a net loss to a net income in the quarter and substantially reducing its year-to-date loss. This indicates effective execution of its growth strategies. However, the persistent material weaknesses in internal control over financial reporting are a serious concern that could lead to future financial restatements or regulatory issues, warranting a cautious approach despite the positive financial momentum.

Positives

• Achieved net income of $1.077 million for Q3 2025, reversing a net loss of $5.957 million in Q3 2024.
• Significantly reduced year-to-date net loss to $2.005 million for 9M 2025, from $50.331 million for 9M 2024.
• Reported strong revenue growth of 16% for Q3 2025 and 13% for 9M 2025.
• Adjusted EBITDA increased by 31% for Q3 2025 and 25% for 9M 2025, indicating improved operational efficiency.
• Patient visits grew by 17% in Q3 2025 and 13% in 9M 2025, driven by a net increase of 764 clinicians.
• Cash and cash equivalents increased to $203.9 million, providing strong liquidity.
• Interest expense, net, decreased by $2.6 million for Q3 2025 and $8.3 million for 9M 2025, primarily due to lower interest rates.
• The company was in compliance with all debt covenants under the 2024 Credit Agreement as of September 30, 2025.

Negatives

• Total Revenue Per Visit (TRPV) decreased year-over-year, primarily due to a rate decrease from a single payor, partially offset by other modest payor rate increases.
• Material weaknesses in internal control over financial reporting, previously reported, continue to exist as of September 30, 2025.
• Disclosure controls and procedures were deemed not effective as of September 30, 2025, due to the identified material weaknesses.
• The company still reported a net loss for the nine months ended September 30, 2025, despite significant improvement.
• Accumulated deficit increased to $(820.294) million as of September 30, 2025, from $(818.289) million at December 31, 2024.

Risks

• Reimbursement rates paid by third-party payors could be reduced, or third-party payors could otherwise restrain the ability to obtain or deliver care to patients, materially harming the business.
• The company may not grow at historical rates or at all, even if key metrics imply future growth, particularly if unable to successfully execute growth initiatives and business strategies.
• Failure to manage growth effectively could lead to higher-than-expected expenses, disproportionate or no revenue increase, and inability to execute business strategy.
• The ability to recruit new clinicians and retain existing clinicians is critical to business growth and performance.
• Operating in a heavily regulated industry, failure to comply with laws and government regulations could result in penalties, significant operational changes, or adverse publicity.
• Dependence on relationships with supported practices (Friendly-Physician Entities) which are not owned; disruption or legal challenges to these arrangements could harm the business.
• Operating in a competitive industry, inability to compete effectively would harm business and financial performance.
• The impact of healthcare reform legislation and other changes in the healthcare industry and spending is currently unknown but may harm the business.
• Security measures failure or breach, leading to unauthorized access to data, could result in significant liabilities, harm reputation, and loss of patients and partners.
• Business depends on the ability to effectively invest in, implement improvements to, and properly maintain the uninterrupted operation and data integrity of information technology and other business systems.
• Existing indebtedness could adversely affect the business and growth prospects.
• Future capital requirements will depend on many factors, including growth rate, timing and extent of spending to acquire new centers, expand into new markets, and expand marketing activities.
• May be required to seek additional equity or debt financing, which may not be available on acceptable terms or at all.

Future Outlook

The company anticipates continued revenue growth driven by its in-house clinician recruiting and new center strategies, as well as increasing patient visits through virtual and in-person sessions. Center costs (excluding depreciation and amortization) and general and administrative expenses are expected to increase in the shortto medium-term due to strategic investments in business expansion and company growth. Plans include partnering with additional hospital systems, large primary care groups, and other specialist groups, with a vision to further integrate mental healthcare services with medical provider partners. The company will continue to evaluate new payor relationships, seek regional rate improvement, and may terminate lower-volume payor contracts. Existing cash and cash equivalents are believed to be sufficient to fund operating and capital needs for at least the next 12 months.

Management Comments

• "We are reimagining mental health through a tech-enabled care delivery model built to expand access, address affordability, improve outcomes and lower overall healthcare costs."
• "We believe our dedicated employment model offers a superior value proposition compared to independent practice."
• "We believe we are an employer of choice in mental health, allowing us to employ highly qualified clinicians."
• "We believe we have significant opportunity to grow our employed clinician base from our current base of 7,996 clinicians employed through our subsidiaries and supported practices."
• "We believe our ability to deliver more accessible, flexible, affordable and effective mental healthcare is a key driver of our patient growth."
• "We believe our payor relationships differentiate us from our competitors and are a critical factor in our ability to expand our market footprint in new regions."
• "We believe we have built a powerful market growth engine that allows us to rapidly grow our presence within our markets and unlock potential latent demand through our differentiated scale, access and affordability."
• "We believe the highly fragmented nature of the mental health market provides us with a meaningful opportunity to selectively pursue acquisitions that meet our standards of high-quality clinical care and align with our mission."
• "We believe that our existing cash and cash equivalents will be sufficient to fund our operating and capital needs for at least the next 12 months from the issuance date of our September 30, 2025 unaudited financial statements, without any additional financing."

Industry Context

The company operates in the U.S. outpatient mental health services industry, which is heavily regulated by federal, state, and local governments concerning licensure, accreditation, government healthcare program participation, reimbursement, and fraud and abuse. Government activity regarding investigations into fraud and abuse statutes has increased. The industry is characterized by a fragmented market, which the company views as an opportunity for selective acquisitions. The recent enactment of the One Big Beautiful Bill Act (OBBBA) on July 4, 2025, introduces changes to Medicaid programs, though the company expects an immaterial impact on its business.

Corporate Governance

Legal Proceedings

• The company is involved from time-to-time in legal actions relating to the ownership and operations of its business.
• Litigation costs for the three and nine months ended September 30, 2025, included cash expenses related to distinct litigation matters, specifically a privacy class action litigation and a compensation model class action litigation.
• For the three and nine months ended September 30, 2024, litigation costs also included expenses related to a securities class action litigation.
• Management believes the company is in substantial compliance with fraud and abuse and other applicable government laws and regulations, and is not aware of any unasserted claims or unreported incidents expected to exceed malpractice insurance coverage limits of $3,000 per claim and an annual aggregate shared limit of $8,000.

Stakeholder Impact

• Shareholders: Potential for increased value due to improved financial performance and growth strategies, but ongoing material weaknesses in internal controls pose a risk to financial reporting reliability.
• Employees/Clinicians: The company aims to be an 'employer of choice' by providing a superior workplace environment, reducing administrative burdens, and expanding the clinician base (net increase of 764 clinicians).
• Patients: Expanded access to comprehensive outpatient mental healthcare through new centers, virtual and in-person care options, and in-network payor relationships, with a focus on improved outcomes.
• Payors: The company partners with payors to provide access to high-quality mental healthcare, aiming to reduce overall medical costs and increase member satisfaction and retention.
• Creditors: The company's compliance with all debt covenants as of September 30, 2025, indicates a stable financial position relative to its debt obligations.

Next Steps

• Continue to drive revenue growth through in-house clinician recruiting and new center strategies.
• Increase patient visits at existing centers by accommodating virtual sessions in addition to in-person visits.
• Strategically invest to expand the business and capture more market opportunity, which is expected to increase center costs in the shortto medium-term.
• Invest to support company growth, which is expected to increase general and administrative expenses in the foreseeable future.
• Partner with additional hospital systems, large primary care groups, and other specialist groups to streamline mental health network needs and drive patient growth.
• Further integrate mental healthcare services with medical provider partners, evolving toward a fully-integrated care model.
• Evaluate new payor relationships and national contracts, while seeking regional rate improvement and potentially terminating lower-volume payor contracts.
• Continue to evaluate the impact of the One Big Beautiful Bill Act (OBBBA) as further information becomes available.
• Continue to enhance the overall control environment and devote substantial effort to remediate identified material weaknesses in internal control over financial reporting.
• Evaluate current and projected resource needs on a regular basis and hire additional qualified resources as needed to support business and projected growth.

Key Dates

Recommendation

The company demonstrates strong operational growth, evidenced by significant increases in revenue, patient visits, and Adjusted EBITDA, coupled with a return to quarterly net income and a substantial reduction in year-to-date losses. These financial improvements suggest effective execution of its growth strategies in a high-demand sector. However, the persistent material weaknesses in internal control over financial reporting are a critical concern. These weaknesses could lead to future financial restatements, regulatory scrutiny, or operational inefficiencies, introducing a notable level of uncertainty. While the financial trajectory is positive, the governance issues warrant a cautious 'hold' recommendation until there is clear evidence of full remediation and sustained effectiveness of internal controls.

Keywords

Mental health services, Outpatient mental health, Healthcare platform, Clinician recruitment, Patient visits, Payor relationships, SEC filing, 10-Q, Financial results, Adjusted EBITDA, Internal control weaknesses, LifeStance Health Group